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Evaluation and construction of diagnostic
criteria for inclusion body myositis
ABSTRACT
Objective: To use patient data to evaluate and construct diagnostic criteria for inclusion body
myositis (IBM), a progressive disease of skeletal muscle.
Methods: The literature was reviewed to identify all previously proposed IBM diagnostic criteria.
These criteria were applied through medical records review to 200 patients diagnosed as having
IBM and 171 patients diagnosed as having a muscle disease other than IBM by neuromuscular
specialists at 2 institutions, and to a validating set of 66 additional patients with IBM from 2 other
institutions. Machine learning techniques were used for unbiased construction of diagnostic
criteria.
Results: Twenty-four previously proposed IBM diagnostic categories were identified. Twelve cat-
egories all performed with high ($97%) specificity but varied substantially in their sensitivities
(11%–84%). The best performing category was European Neuromuscular Centre 2013 probable
(sensitivity of 84%). Specialized pathologic features and newly introduced strength criteria (com-
parative knee extension/hip flexion strength) performed poorly. Unbiased data-directed analysis
of 20 features in 371 patients resulted in construction of higher-performing data-derived diag-
nostic criteria (90% sensitivity and 96% specificity).
Conclusions: Published expert consensus–derived IBM diagnostic categories have uniformly high
specificity but wide-ranging sensitivities. High-performing IBM diagnostic category criteria can
be developed directly from principled unbiased analysis of patient data.
Classification of evidence: This study provides Class II evidence that published expert consensus–
derived IBM diagnostic categories accurately distinguish IBM from other muscle disease with
high specificity but wide-ranging sensitivities. Neurology® 2014;83:426–433
GLOSSARY
ANRI5Australian Neuromuscular Research Institute;BWH5 Brigham andWomen’s Hospital;CD5 clinically defined;CPD5
clinicopathologically defined; ENMC 5 European Neuromuscular Centre; IBM 5 inclusion body myositis; IM 5 Institute of
Myology; JHMI 5 Johns Hopkins Medical Institutions; MHC-1 5 major histocompatibility complex class I; MMT 5 manual
muscle testing;MRC5Medical Research Council; PD5 pathologically defined; UWASH5University of Washington Seattle.
Sporadic inclusion body myositis (IBM) is a progressive autoimmune and degenerative disorder
of muscle of unknown cause. Research diagnostic categories for IBM are important in the re-
porting of research on cohorts of patients with IBM and are essential for the conduct of IBM
clinical therapeutic trials. Formal research diagnostic criteria and categories for IBM have been
proposed since 1987 by individual authors1–4 and through publications of consensus expert
opinions developed in 5 meetings in 1995,5 1996,6,7 2008,8 2009,9 and 2011.10 These pub-
lications have created features (e.g., “presence of quadriceps weakness”), categories (Boolean
algebraic combinations of features; e.g., definite), and schemes (combinations of categories; e.g.,
definite, probable, and possible). All of these consensus features, categories, and schemes were
reported in the absence of published data on their sensitivity and specificity for IBM among
muscle diseases.
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To understand the basis and applicability of
existing IBM diagnostic criteria and categories,
we separately studied the performance of fea-
tures, categories, and schemes in a large cohort
of patients diagnosed with IBM by their treat-
ing physicians and in patients diagnosed with
muscle diseases other than IBM at 4 different
institutions. In addition, we demonstrate a
method for developing empirical data-derived
IBM diagnostic criteria.
METHODS We examined the literature for all published IBM
diagnostic schemes, separating features and categories. We retro-
spectively reviewed medical records of 200 patients diagnosed
during clinical care as definitely having IBM and of 171 patients
diagnosed as definitely having a muscle disease other than IBM by
neuromuscular specialists at Brigham and Women’s Hospital
(BWH; n 5 182) and Johns Hopkins Medical Institutions
(JHMI; n 5 189). No uniform criteria for diagnosis had been
systematically applied; clinicians made these diagnoses in the
course of ordinary clinical practice. Strength criteria were assessed
according to Medical Research Council (MRC) manual muscle
testing (MMT) scores. Strength criteria were interpreted as satis-
fied if they were met on one or both sides of the body. No sep-
arate review of muscle pathologic slides or additional performance
of studies other than what had been performed for clinical care
and recorded in medical records was performed. For the research
question pertaining to diagnostic sensitivity and specificity of
various criteria against the gold standard of clinical diagnosis by
treating clinicians, level of evidence Class II applies because this is
a case-control study of a broad spectrum of persons with and
without the disease, and clinical diagnosis was determined
without reference to criteria sets.
Non-IBM diagnoses (appendix e-1 on the Neurology® Web
site at Neurology.org) included inflammatory myopathies (n 5
87; 51%) and inherited myopathies (n5 43; 25%), of which 20
patients had myopathies with prominent rimmed vacuoles (e.g.,
hereditary inclusion body myopathies or myofibrillar myopathy).
Medical records from 2 other cohorts of patients diagnosed as
having IBM by neuromuscular specialists at the Australian Neu-
romuscular Research Institute (ANRI; n5 42) and University of
Washington Seattle (UWASH; n5 24) had more limited review,
confined to MMT scores in selected muscles. Machine learning
algorithms were implemented using the software package Orange
(appendix e-2).11
Standard protocol approvals, registrations, and patient
consents. All patient data were studied under protocols approved
by institutional review boards.
RESULTS Applicability of existing IBM research
diagnostic criteria to patients. We studied the applica-
bility of 10 different schemes of IBM diagnostic crite-
ria1–10 comprising 24 categories. We found that 12
categories could be applied to patients (table), while
12 other categories were not further studied for the
following reasons. Two European Neuromuscular
Centre (ENMC 1997 probable and ENMC 1997 def-
inite) categories6 were subsequently replaced with
revised versions in the year 20007; only the revised
categories were analyzed here. Four categories lacked
specificity for IBM and were not further analyzed: 3
1987 definite, probable, and possible1 categories lack a
requirement for the microscopic detection of inflamma-
tory cells in muscle biopsy specimens, allowing patients
with genetic disorders with rimmed vacuoles to be cat-
egorized as IBM; and a 1991 criteria set2 indicated that
filamentous inclusions were pathognomonic of IBM,
although these were known to be present in a number
of hereditary distal myopathies.12 The category Griggs
probable was of uncertain existence, having been re-
ported in a single review article where it had been
referred to in text as Griggs possible.4 Five categories
have criteria we were unable to unambiguously apply to
patients for the following reasons: ENMC 1997 possi-
ble (uncertainty about application of the required crite-
rion: “IBM is most often a disease of middle-aged or
elderly men”)6; Western Australia 2002 definite,
probable, and possible (uncertainty about minimal
pathologic features required)3; and Institute of
Myology 2010 pathologically defined (circularly
defined clinical criteria of “consistent with IBM”).9
Sensitivity and specificity of IBM categories and features.
Next, we determined the sensitivity (proportion of 200
patients diagnosed with IBM meeting diagnostic cate-
gory criteria) and specificity (proportion of 171 patients
diagnosed as not having IBM not meeting IBM diag-
nostic category criteria) of these 12 diagnostic categories
from 5 different schemes (figure 1, A and B). All cat-
egories had very high specificity (range 98%–100%)
but differed substantially in sensitivities (range 11%–
84%). The best performing categories were ENMC
2013 probable and Institute of Myology (IM) 2010
possible (sensitivities of 84% and 77%, respectively).
The least sensitive categories were Griggs definite/
MRC 2010 PD (whose criteria are identical) and
ENMC 2013 clinicopathologically defined (CPD)
(sensitivities of 11% and 15%, respectively). Only
45% of patients fulfilled either the MRC 2010 PD
or clinically defined (CD) categories, and 60% fulfilled
either the ENMC 2013 CPD or CD categories that
evolved from refinements in the MRC 2010 scheme.
To understand the substantial differences in the
sensitivities of these categories, we studied the sensi-
tivity and specificity of the 25 individual features used
among these categories (figure 1, C and D). Features
pertaining to demographics (e.g., age at onset), tem-
poral course, and serum creatine kinase limits gener-
ally had high sensitivities but very low specificities. In
contrast, certain strength and pathologic criteria had
high specificities but very low sensitivities. The least
sensitive strength feature “weakness of knee extension
greater than hip flexion,” a requirement for the MRC
2010 CD and IM 2010 CD categories, had 47%
sensitivity. Similarly, certain pathologic features were
also highly specific but of very low sensitivity (e.g.,
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the requirement for electron microscopy tubulofila-
ments had only 10% sensitivity).
Category failure rates and reasons. To understand
whether the low sensitivities of certain categories were
attributable to the low sensitivities of certain features,
we examined the specific features that resulted in fail-
ure to meet specific category criteria. This enabled us
to determine the proportion of patients failing to
meet that category’s requirements (failure rates) and
the single most common feature responsible for that
failure (figure 2A).




ENMC 2000 definite7 AND(2,4,14a,15,OR(10,11,16))
ENMC 2000 probable7 AND(2,4,14a,OR(10,11,15))
MRC 2010 PD8 AND(14a,15,OR(16,17))
MRC 2010 CD8 AND(1b,3b,7,9,OR(14a,15,21),NOT(OR(16,17)))
MRC 2010 possible8 AND(1b,3b,OR(7,9),OR(14a,15,21),NOT(OR(16,17)))
IM 2010 CD9 AND(1a,3a,6,7,9,OR(14b,21),NOT(OR(16,17,18)))
IM 2010 possible9 AND(1a,3a,6,OR(7,9),OR(14b,21),NOT(OR(16,17,18)))
ENMC 2013 CPD10 AND(1c,3b,5b,14b,15,21,OR(8,9),OR(16,17,18,19,20))
ENMC 2013 CD10 AND(1c,3b,5b,8,9,OR(14b,15,16,17,18,19,20,21),NOT(AND(14b,15,21,OR
(16,17,18,19,20))))




1. Age lower limit 7. KE weaker than HF
a. Age .30 y 8. KE equal to or weaker than HF
b. Age .35 y 9. FF weaker than SA
c. Age .45 y 10. WF weaker than WE
2. Sporadic 11. FF weakness
Temporal aspect 12. Quads #MRC 4
3. Duration minimum 13. Proximal/distal weakness arms/legs
a. .6 mo Muscle pathology
b. .12 mo 14. Inflammation
4. Slow progression a. Invasion of nonnecrotic fibers
Laboratory studies b. Endomysial inflammation
5. Serum CK maximum 15. RVs
a. 123 ULN 16. EM tubulofilaments
b. 153 ULN 17. Amyloid




Abbreviations: CD5 clinically defined; CK 5 creatine kinase; CPD5 clinicopathologically defined; EM5 electron microscopy;
ENMC5 European Neuromuscular Center; FF5 finger flexion; HF5 hip flexion; IBM5 inclusion body myositis; IM5 Institute
of Myology; KE5 knee extension; MHC-15 major histocompatibility complex class I; MRC 5 Medical Research Council; PD5
pathologically defined; RV 5 rimmed vacuole; SA 5 shoulder abduction; SMI31 5 phosphorylated neurofilament antigen;
TDP-43 5 TAR DNA-binding protein-43; ULN 5 upper limit of normal; WE 5 wrist extension; WF 5 wrist flexion.
Categories analyzed and their criteria. Years (2000, 2010, and 2013) refer to the year of publication rather than year of
conference/workshop. For example, MRC 2010 CD category was published in 2010 and requires features 1b and 3b and
7 and 9 and either (14a, 15, or 21) and not (16 or 17).
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Certain categories performed poorly in part not
because patients lacked typical features of IBM but
paradoxically because patients indeed had such fea-
tures. For example, the MRC 2010 CD category (fail-
ure rate of 65%), as well as the MRC 2010 possible,
IM 2010 possible, and IM 2010 CD categories,
exclude patients if they have tubulofilaments or amy-
loid present. The ENMC 2013 CD and ENMC
2013 probable categories exclude patients for having
too many pathologic features, although such patients
instead meet ENMC 2013 CPD criteria.
Certain categories rely on specialized pathologic fea-
tures, often not performed or performed and found to
be absent, even at tertiary referral centers. The Griggs
definite/MRC 2010 PD categories (failure rates 89%),
and ENMC 2013 CPD (failure rate 85%) category
both rely on low sensitivity features, such as electron
microscopy–demonstrated tubulofilaments, or Congo
red–demonstrated amyloid. Electron microscopy was
performed in 24% of our patients with IBM and
showed tubulofilaments in only 35% of those in whom
it was done. Congo red staining was performed in 36%
of our patients and revealed amyloid in only 19% of
those in whom it was done.
Other categories performed poorly because of the
low sensitivity of certain strength criteria. The best per-
forming strength criteria was “finger flexion weakness”
(2% failure rate) and the worst performing was “weak-
ness of knee extension greater than hip flexion” (53%
failure rate; figure 2B). The Griggs possible criterion of
“proximal and distal weakness of arms and legs” was
also quite limiting (47% failure rate). The recently
proposed categories of MRC 2010 CD (65% failure
rate) and IM 2010 CD (63% failure rate) both fail
Figure 1 Sensitivities and specificities of IBM categories and features
(A, B) IBM categories. (C, D) IBM features. CD 5 clinically defined; CK 5 creatine kinase; CPD 5 clinicopathologically defined; Def 5 definite; EM 5 electron
microscopy; ENMC5 European Neuromuscular Center; FF5 finger flexion; HF5 hip flexion; IBM5 inclusion body myositis; IM5 Institute of Myology; KE5
knee extension; MRC 5 Medical Research Council; PD 5 pathologically defined; Poss 5 possible; Prob 5 probable; RV 5 rimmed vacuoles; SA 5 shoulder
abduction; TF 5 tubulofilaments; WE 5 wrist extension; WF 5 wrist flexion.
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primarily because of the “weakness of knee extension
greater than hip flexion” criterion, while the ENMC
2013 CD (failure rate 43%) primarily fails because of
the similar “weakness of knee extension equal to or
greater than hip flexion” criterion.
The comparative knee extension/hip flexion crite-
ria we found to be of low sensitivity were developed at
3 workshops (2008 MRC meeting in Oxford,8 2009
IM meeting in Paris,9 and 2011 ENMC workshop in
Naarden10) and have been incorporated into 7 of the
most recently developed categories studied. We there-
fore wondered whether data from 2 of our institutions
(BWH and JHMI) were representative of other in-
stitutions’ experience. Accordingly, we examined
MMT data from 2 other institutions, ANRI and
UWASH, in an additional 66 patients with IBM,
for a total of 266 patients with IBM. We found con-
sistent strength criteria failure rates at all 4 institutions
(figure 2C). Thus, “finger flexion weakness” had the
lowest failure rates (BWH/JHMI/ANRI/UWASH:
0%/3%/0%/25%, respectively) while “weakness of
knee extension greater than hip flexion” had the high-
est failure rates (BWH/JHMI/ANRI/UWASH: 68%/
47%/38%/66%, respectively).
We also studied whether disease duration might
affect the proportion of patients failing various
strength criteria (figure 2D). For our BWH/JHMI
cohort of 200 patients with IBM, the mean duration
of IBM symptoms was 6.7 years. The failure rate for
the best performing strength criterion “weakness of
finger flexion” was low in both early disease (0% for
duration 1–3 years) and late disease (5% for duration
.10 years). In contrast, the failure rate for “weakness
of knee extension greater than hip flexion” was higher
early in disease (60% for duration 1–3 years) than in
late disease (45% for duration .10 years). All of the
Figure 2 Failure rates and reasons for IBM diagnostic criteria
(A) Failure rates for published IBM diagnostic categories according to most common criteria failed. (B) Failure rates of strength criteria. Ambiguity results from
meeting strength criteria on one side of the body but failing on the other side. (C) Consistency of strength criteria failure rates at 4 institutions. The criterion
of “finger flexion weakness” (FF ,5) performed best and that of “weakness of knee extension greater than hip flexion” performed worst at all of 4 different
institutions. (D) Failure rates by disease duration. Disease duration has little impact on finger flexion criteria failure but a consistent impact on all knee extension–
related criteria, with greater failure rates for 1–3 and 3–5 years than 5–10 and.10 years for KE# HF, KE, HF, and KE# 4. AMY5 amyloid; ANRI5 Australian
Neuromuscular Research Institute; BWH5 Brigham andWomen’s Hospital; CD5 clinically defined; CPD5 clinicopathologically defined; Def5 definite; ENMC5
European Neuromuscular Center; FF 5 finger flexion; HF 5 hip flexion; IBM5 inclusion body myositis; IM5 Institute of Myology; INV 5 invasion of non-necrotic
muscle fibers; JHMI5 Johns HopkinsMedical Institutions; KE5 knee extension; MRC5Medical Research Council; PD5 pathologically defined; Poss5 possible;
Prob 5 probable; SA 5 shoulder abduction; TF 5 tubulofilaments; UWASH 5 University of Washington Seattle; WE 5 wrist extension; WF 5 wrist flexion.
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knee extension–based criteria tended toward higher
failure rates in early disease than in late disease.
Structure of IBM classification schemes. We studied the
manner in which 5 published classification schemes
(Griggs 1995, ENMC 2000, MRC 2010, IM 2010,
and ENMC 2013) have created or avoided overlap
or gaps of their categories (figure 3). The ENMC
2000 scheme is a strictly nested hierarchy, whereas
the Griggs classification system is nonoverlapping non-
hierarchical. Thus, all patients who satisfy ENMC
2000 definite criteria also satisfy ENMC possible cri-
teria, whereas patients only satisfy Griggs possible or
Griggs definite criteria, but not both.
All other schemes had a mixture of hierarchical and
nonhierarchical structures, some with gaps. Thus, the
MRC 2010 (figure 3C) scheme has a hierarchical
nested category (all patients meeting CD also meet
possible criteria) but also a nonoverlapping category
(PD, some of whose inclusion criteria are exclusion
criteria for CD and possible). However, these criteria
have a gap, in that a patient without rimmed vacuoles
can meet MRC 2010 CD criteria by the presence of
major histocompatibility complex class I (MHC-1)
upregulation, but if that patient additionally had tubu-
lofilaments, they would no longer meet CD criteria,
yet would not graduate to the CPD category. Such a
patient would be eliminated from the scheme entirely,
failing to meet any MRC 2010 category. A similar
phenomenon occurs with IM 2010 categories.
Lastly, the most recently proposed ENMC 2013
scheme is similar to the MRC 2010 scheme with both
hierarchical and nonhierarchical categories, but elim-
inates any gaps (figure 3D). However, this scheme
contains partial overlap of categories. Thus, patients
satisfying CPD criteria can satisfy all 3 (CPD, CD,
and probable) categories, only 2 categories (CPD and
probable), or only 1 category (CPD alone).
Application of machine learning to construct data-
derived IBM diagnostic criteria. We constructed simple
IBM diagnostic criteria by using only highly perform-
ing features. A range of machine learning algorithms
performed classification with higher diagnostic accur-
acy (98%–99%) than currently used diagnostic crite-
ria (appendix e-2). These approaches are probably not
suited to routine clinical practice use, but their unbi-
ased selection of features suggests best performing com-
binations. Thus, classification trees (appendix e-2)
indicated that finger flexion weakness, rimmed vacuoles,
and invasion of nonnecrotic muscle fibers used in com-
bination were highly performing features. Indeed, the
following data-derived criteria had 90% sensitivity and
96% specificity among 371 patients: (1) finger flexor or
quadriceps weakness, and (2) endomysial inflammation,
and (3) either invasion of nonnecrotic muscle fibers or
rimmed vacuoles.
DISCUSSION Diagnostic criteria for IBM are neces-
sary to define inclusion criteria in clinical trials, and
are therefore a prerequisite for eventual regulatory
approval of an IBM therapeutic. From 24 IBM diag-
nostic categories that have been proposed since 1987,
we found that 12 had been updated, had poor speci-
ficity, or had sufficient ambiguities precluding their
application. Of the remaining 12 categories, we
found that although all had very high specificities of
97% or greater, some had poor sensitivities, as low
as 11%, while the best performing category (ENMC
2013 probable) had a sensitivity of 84%. We traced
the poor performance of many IBM categories to
either highly specific but very insensitive pathologic
criteria or recently introduced comparison strength
criteria with low sensitivity. Poor performance of cer-
tain specialized pathologic features is at least partially
attributable to not being frequently performed in
clinical practice. Although these pathologic features,
in addition to recently identified biomarkers such as
p62 and TDP-43 (TAR DNA-binding protein-43)
Figure 3 Hierarchical structure of 4 schemes represented as Venn diagrams
(A) Griggs 1995 categories are nonoverlapping and nonhierarchical. (B) ENMC 2000 catego-
ries probable and definite are a nested hierarchy: all patients who meet definite criteria also
meet probable criteria, and no gaps are present if a patient with probable gains additional
features. (C) MRC 2010 categories are a hybrid between nested hierarchy (all CD patients
meet Poss criteria) and nonoverlapping nonhierarchical (no PD patients meet CD or Poss cri-
teria). This scheme contains a gap (both CD and Poss patients can gain an inclusion body
myositis feature, such as tubulofilaments, resulting in loss of CD or Poss status, but yet
not graduate to PD). (D) ENMC 2013 criteria are a hybrid between nested hierarchy (all
CD patients meet Prob criteria) and an overlapping nonhierarchical category (CPD patients
can also meet Prob or CD criteria, or they can fail to meet either Prob or CD criteria). CD 5
clinically defined; CPD 5 clinicopathologically defined; Def 5 definite; ENMC 5 European
Neuromuscular Center; MRC 5 Medical Research Council; PD 5 pathologically defined;
Poss 5 possible; Prob 5 probable.
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immunoreactivity, might be more frequently present
in specialized research laboratories, their performance
by clinical pathology laboratories in the course of
clinical care is uncommon. Nevertheless, the use of
these specialized pathologic features in the MRC
2010 PD category, which has been advocated for use
in clinical trials,9,13 and the ENMC 2013 CPD may
be limiting in that only 11% and 15% of 200 patients
with IBM fulfill these categories’ criteria, respectively.
In addition, we found that recently introduced
comparative strength criteria pertaining to knee exten-
sion and hip flexion, adopted into 7 new categories,
were of low sensitivity. Of 266 patients with IBM at
4 institutions in the United States and Australia, a
mean of 55% (range 38%–69%) fail to meet “weak-
ness of knee extension greater than hip flexion” and a
mean of 41% (range 21%–63%) fail to meet “weak-
ness of knee extension equal to or greater than hip
flexion” criteria. The low sensitivity of these criteria
across our 4 institutions is otherwise consistent with
existing literature that has emphasized substantial
weakness of hip flexion in IBM.12,14,15 We also note
that in our cohort, the lower proportion of shorter-
duration patients than longer-duration patients meet-
ing the “weakness of knee extension equal to or greater
than hip flexion” criterion would bias clinical trials
using it toward longer-duration, more severely affected
patients, which is likely not ideal for development of
therapeutics aimed at treating patients with IBM
before extensive muscle loss and fibrosis are present.
Some of our results can be contrasted with a recent
single-institution study of 67 patients with IBM.13
This study used different criteria for several categories
than we did. Their Griggs possible category5 required
rimmed vacuoles as an inclusion criterion, which we
did not require. The ENMC 2013 CPD criteria used
in this previous study required the presence of MHC-
1, which is not listed as an ENMC 2013 requirement
as recently published.10 Only 18% of their patients
failed the criterion “weakness of knee extension equal
to or greater than hip flexion” in contrast to 21% to
63% of patients across our 4 institutions. This previ-
ous study and ours both found low sensitivity of
ENMC 2013 CPD (16% previous study, 15% our
study) and ENMC 2013 CD (39% previous study,
57% our study) categories.
More generally, several considerations for future
IBM criteria development applicable to clinical trial
enrollment can be noted. The use of pathologic meth-
ods not routinely performed might be avoided. Crite-
ria should not exclude patients because of the
presence of typical features. Ambiguous strength cri-
teria that might be met on one side but not the other
side of the body should be avoided. Comparison
strength criteria (comparing one muscle group with
another) may result in patients previously meeting
criteria subsequently failing to meet such criteria (e.g.,
knee extension weaker than hip flexion at one point
in disease, but not as hip flexion weakness progresses).
Circular definitions (e.g., IM 2010 PD having clinical
criterion of “consistent with IBM”) should be avoided,
because they make category membership undetermin-
able. Lastly, because all the current “probable” and “pos-
sible” categories have high specificity ($97%), these
could in fact be called “definite” categories.
Schemes that have nonhierarchical natures should
be used cautiously because these may result in para-
doxical classification (e.g., meeting stringent MRC
2010 PD criteria but failing the weaker MRC 2010
possible criteria). In contrast, all patients meeting
ENMC 2000 definite automatically meet the ENMC
2000 probable category. Overlapping nonhierarchical
approaches can also create unusual behavior: some pa-
tients meeting the ENMC 2013 CPD category meet
ENMC 2013 probable or both ENMC 2013 proba-
ble and ENMC 2013 CD, while others meet neither.
Nonhierarchical structures can also create unintended
gaps, in which adding an additional typical feature of
IBM can cause a patient who satisfies one category to
be eliminated from that category as well as all of a
scheme’s categories. For example, a patient who has
rimmed vacuoles but not myofiber invasion can meet
the MRC 2010 CD criteria, but if that same patient
has an electron microscopy study showing tubulofila-
ments (a feature that should suggest the diagnosis
more strongly), they will then fail to meet criteria
for any of the categories.
Over 18 years during which 5 workshops have
produced publications of IBM diagnostic crite-
ria,5,6,8–10 no studies of the performance of these cri-
teria have been published, until this year.13 Herein,
we have shown that such criteria can be empirically
derived in a principled fashion directly from patient
data through the use of unbiased machine learning
approaches. Such data-derived criteria performed well
in our cohort with 90% sensitivity and 96% specific-
ity, although we recognize that some patients with
severe inflammatory myopathies or inherited vacuolar
myopathy may meet these criteria. The use of data-
derived criteria is an approach that can be used in
future IBM criteria development.
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